{"filings":[{"id":1249359,"accession_number":"0001601485-26-000050","cik":1601485,"company_name":"Elicio Therapeutics, Inc.","ticker":"ELTX","form_type":"8-K","filed_at":"2026-06-24T20:05:56+00:00","items":["7.01","9.01"],"status":"ready","headline":"Elicio hosts KOL event on ELI-002 7P for metastatic mKRAS PDAC; no new data disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Virtual KOL event on June 24, 2026 featured Dr. Zev Wainberg (UCLA) and Dr. Peter Hosein (U. Miami).","Event discussed path forward for ELI-002 7P in metastatic mutant KRAS-driven pancreatic ductal adenocarcinoma.","No specific clinical data, enrollment updates, or financial guidance were included in the filed material."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":202503322.98607242,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1093517,"accession_number":"0001601485-26-000048","cik":1601485,"company_name":"Elicio Therapeutics, Inc.","ticker":"ELTX","form_type":"8-K","filed_at":"2026-06-17T12:03:10+00:00","items":["8.01","9.01"],"status":"ready","headline":"Elicio reports 3 complete responses post-ELI-002 7P with checkpoint inhibition in mPDAC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["100% confirmed complete radiographic and metabolic responses in 3 patients who progressed on ELI-002 7P and received nivolumab-based therapy.","Complete responses rarely observed (0-8%) in metastatic pancreatic cancer; all 3 patients are MSS/MMR-p, historically refractory to immunotherapy.","Two patients maintained complete responses ≥8 months; one ongoing >13 months with persistent mKRAS-specific T cells.","Elicio plans Phase 1 study in first-line metastatic mKRAS PDAC combining ELI-002 7P with chemotherapy and anti-PD-1, subject to funding.","Virtual KOL event June 24, 2026, to discuss observations with UCLA and University of Miami oncologists."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":202503322.98607242,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1040316,"accession_number":"0001601485-26-000046","cik":1601485,"company_name":"Elicio Therapeutics, Inc.","ticker":"ELTX","form_type":"8-K","filed_at":"2026-06-15T13:21:02+00:00","items":["8.01","9.01"],"status":"ready","headline":"Elicio Phase 2 AMPLIFY-7P misses primary DFS endpoint; positive R0 subgroup guides Phase 3","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["AMPLIFY-7P did not meet primary endpoint of DFS in ITT; R1 resection imbalance (19% vs 10%) favored observation arm.","Post-hoc analysis in R0 patients showed HR 0.65 (p=0.048); mDFS 23.8 mo vs 12.8 mo; 84% of study population.","mKRAS-specific T cell responses strongly correlated with DFS (HR 0.22, p<0.0001, n=90).","Refined Phase 3 plan targets R0 resected patients with additional dosing; cash runway into Q4 2026; exploring financing.","Favorable safety: no treatment-related discontinuations or deaths."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":202503322.98607242,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":13047,"accession_number":"0001601485-26-000041","cik":1601485,"company_name":"Elicio Therapeutics, Inc.","ticker":"ELTX","form_type":"8-K","filed_at":"2026-05-11T20:09:10+00:00","items":["2.02","9.01"],"status":"ready","headline":"Q1 net loss $11.8M ($0.65/sh); Phase 2 DFS readout mid-2026; cash runway into Q4","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net loss $11.8M ($0.65/sh) vs $11.2M ($0.87/sh) YoY; R&D $6.8M, G&A $3.8M.","Cash $14.9M at Mar 31; raised $13M via ATM in Q1-Q2; expected runway into Q4 2026.","Phase 2 AMPLIFY-7P primary DFS analysis for ELI-002 7P in PDAC expected mid-2026; fewer events observed.","Company remains blinded; after DFS readout, plans End-of-Phase 2 FDA meeting for Phase 3 design."],"consensus_eps_estimate":-0.4743,"consensus_eps_actual":-0.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":202503322.98607242,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106040,"accession_number":"0001601485-26-000032","cik":1601485,"company_name":"Elicio Therapeutics, Inc.","ticker":"ELTX","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"Elicio Therapeutics enters $100M ATM facility; terminates prior $40M JonesTrading ATM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company entered ATM sales agreement to sell up to $100M of common stock through B. Riley Securities, JonesTrading, and Ladenburg Thalmann.","Agents will receive 3% commission on gross proceeds from any shares sold under the program.","Company terminated prior $40M ATM agreement with JonesTrading from June 2024, effective immediately.","Sales will be made at-the-market on Nasdaq under existing S-3 registration statement.","Company not obligated to sell any shares; program provides capital raising flexibility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":202503322.98607242,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106039,"accession_number":"0001601485-26-000026","cik":1601485,"company_name":"Elicio Therapeutics, Inc.","ticker":"ELTX","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Elicio Therapeutics reports FY2025 net loss of $39.5M; Phase 2 PDAC trial DFS readout expected 1H 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for 2025 was $39.5M ($2.58 per share), compared to $51.9M ($4.25) in 2024.","R&D expense decreased to $24.9M from $33.7M; G&A expense increased to $12.8M from $11.3M.","Cash and equivalents $18.6M as of Dec 31, 2025; runway into Q3 2026 beyond expected Phase 2 DFS analysis.","Phase 2 AMPLIFY-7P trial in PDAC: fewer progressions and deaths observed than projected; primary DFS analysis on track for 1H 2026.","Raised net ~$4.9M in Q4 2025 and ~$6.3M in Q1 2026 via at-the-market program; appointed Marc J. Wolfgang as CTO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":202503322.98607242,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122330,"accession_number":"0001601485-25-000123","cik":1601485,"company_name":"Elicio Therapeutics, Inc.","ticker":"ELTX","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Elicio Q3 net loss $10.1M ($0.60/sh); Phase 2 DFS analysis pushed to 1H 2026 on fewer events","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Phase 2 AMPLIFY-7P: fewer disease progressions/deaths than projected; event-driven primary DFS analysis now expected 1H 2026.","Raised ~$11.1M gross via ATM since Q3 start; cash $20.6M at Sep 30, extending runway through Q2 2026.","Q3 net loss $10.1M ($0.60/sh) vs $18.8M ($1.39) YoY; R&D expense down to $5.0M from $7.2M.","IDMC recommended continue Phase 2 without modifications; after DFS analysis, will request End of Phase 2 FDA meeting."],"consensus_eps_estimate":-0.561,"consensus_eps_actual":-2.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":202503322.98607242,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139033,"accession_number":"0001193125-25-205522","cik":1601485,"company_name":"Elicio Therapeutics, Inc.","ticker":"ELTX","form_type":"8-K","filed_at":"2025-09-17T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Elicio reports 99% T cell response rate in Phase 2 AMPLIFY-7P trial of ELI-002 7P","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ELI-002 7P induced mKRAS-specific T cell responses in 99% of evaluable patients (89 of 90).","Average fold increase 145.3x over baseline; median 44.3x; 80% of patients above 9.5x threshold correlated with clinical activity in Phase 1.","85% of patients had combined CD4+CD8 T cell response vs 75% in Phase 1; 67.4% responded to all 7 mKRAS antigens vs 50%.","IDMC recommended continue without modifications after interim safety/efficacy review; company remains blinded to clinical outcomes.","Final disease-free survival analysis anticipated in Q4 2025; Phase 2 includes both MRD+ and MRD- patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":202503322.98607242,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139032,"accession_number":"0001601485-25-000114","cik":1601485,"company_name":"Elicio Therapeutics, Inc.","ticker":"ELTX","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Elicio publishes Phase 1 ELI-002 data in Nature Medicine: OS 28.94 months, 77% risk reduction","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["At 19.7 mo median follow-up, median OS increased to 28.94 months from 16.33 months in Phase 1 AMPLIFY-201.","Above-threshold T cell responses gave 77% reduction in death risk (HR 0.23) and 88% reduction in relapse risk (HR 0.12).","84% (21/25) of patients had tumor biomarker responses; 24% (6/25) achieved complete biomarker clearance.","Final event-driven DFS analysis for Phase 2 AMPLIFY-7P study of ELI-002 7P in PDAC anticipated Q4 2025.","ELI-002 was well tolerated; no dose-limiting toxicities or ≥Grade 3 treatment-related adverse events observed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":202503322.98607242,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139031,"accession_number":"0001601485-25-000108","cik":1601485,"company_name":"Elicio Therapeutics, Inc.","ticker":"ELTX","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Elicio Q2 net loss $10.6M; IDMC positive for ELI-002 Phase 2; DFS readout Q4 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["IDMC recommended continue ELI-002 Phase 2 pancreatic study without modification; final DFS analysis expected Q4 2025.","Net loss $10.6M in Q2 2025 vs $7.2M in Q2 2024; R&D expense decreased to $7.0M.","Cash $22.1M at June 30, 2025; secured $10M non-dilutive financing in Q2 2025.","Company expects cash to fund operations into Q1 2026, beyond Phase 2 final analysis."],"consensus_eps_estimate":-0.6987,"consensus_eps_actual":-1.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":202503322.98607242,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139030,"accession_number":"0001601485-25-000099","cik":1601485,"company_name":"Elicio Therapeutics, Inc.","ticker":"ELTX","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Elicio Therapeutics announces IDMC positive recommendation to continue Phase 2 pancreatic cancer trial to final analysis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IDMC recommended AMPLIFY-7P trial continue to final analysis without modifications based on pre-specified interim review of safety and efficacy.","Final disease-free survival analysis anticipated in Q4 2025; company remains blinded to trial outcomes.","Cash runway extends into Q1 2026, past the expected final DFS readout.","Elicio previously reached FDA alignment on key elements of planned pivotal Phase 3 study design.","ELI-002 7P is an off-the-shelf immunotherapy targeting seven KRAS mutations in pancreatic ductal adenocarcinoma."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":202503322.98607242,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156546,"accession_number":"0001601485-25-000096","cik":1601485,"company_name":"Elicio Therapeutics, Inc.","ticker":"ELTX","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["1.01","2.03","3.02","7.01","9.01"],"status":"ready","headline":"Elicio Therapeutics secures $10M senior secured note from board-affiliated investor","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $10M promissory note to GKCC (controlled by board member); interest rate up to 12.5%.","Warrant to purchase 103,225 shares at $7.75 issued; immediately exercisable, 5-year term.","Proceeds plus current cash expected to fund operations into Q1 2026.","AMPLIFY-7P Phase 2 interim analysis for ELI-002 in PDAC anticipated in Q3 2025.","Note matures June 3, 2028; 24-month interest-only period with lump-sum interest payment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":202503322.98607242,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156545,"accession_number":"0001601485-25-000076","cik":1601485,"company_name":"Elicio Therapeutics, Inc.","ticker":"ELTX","form_type":"8-K","filed_at":"2025-05-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Elicio Therapeutics stockholders elect two directors, ratify auditor at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Karen J. Wilson elected with 8,588,077 votes for, 420,412 against; 2,154,961 broker non-votes.","Robert R. Ruffolo Jr. elected with 8,980,091 votes for, 28,388 against; 2,154,961 broker non-votes.","Baker Tilly US, LLP ratified as auditor for FY2025 with 11,133,552 votes for, 29,923 against.","Quorum of 70.1% achieved with 11,172,771 shares voted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":202503322.98607242,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156544,"accession_number":"0001601485-25-000072","cik":1601485,"company_name":"Elicio Therapeutics, Inc.","ticker":"ELTX","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Elicio reports Q1 net loss of $11.2M; cash into Q4 2025; Phase 2 interim analysis Q3 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $11.2M ($0.87 per share) for Q1 2025 vs $11.8M ($1.15) in Q1 2024.","R&D expense $7.8M, G&A $3.0M; cash and equivalents $18.4M at March 31, 2025.","DFS event-driven interim analysis of Phase 2 AMPLIFY-7P trial (ELI-002 in PDAC) expected in Q3 2025.","FDA alignment on key design elements of planned Phase 3 study for ELI-002 in resected mKRAS PDAC.","Appointed Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer in March 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":202503322.98607242,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174969,"accession_number":"0001601485-25-000046","cik":1601485,"company_name":"Elicio Therapeutics, Inc.","ticker":"ELTX","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Elicio Therapeutics reports year-end 2024 results; press release text unreadable","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Filing announces financial results for year ended Dec 31, 2024 and corporate updates.","Attached press release (Exhibit 99.1) contains extensive encoding corruption; specific figures not extractable.","No legible quantitative guidance or material non-financial updates identified in the exhibit.","Management change or other items not mentioned; only operational update alluded to."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":202503322.98607242,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174968,"accession_number":"0001601485-25-000022","cik":1601485,"company_name":"Elicio Therapeutics, Inc.","ticker":"ELTX","form_type":"8-K","filed_at":"2025-03-24T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Elicio Therapeutics appoints Preetam Shah as Chief Strategy and Financial Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Preetam Shah appointed Chief Strategy and Financial Officer effective March 24, 2025; will become Principal Financial Officer and Principal Accounting Officer on April 1, 2025.","Annual base salary $480,000; target bonus of 40% of base; initial option grant equal to 1.2% of outstanding shares as of April 15, 2025, vesting over 4 years.","Shah previously served as CFO/CBO at Cidara Therapeutics (Sept 2021–Feb 2025) and CFO & Treasurer at Brainstorm Cell Therapeutics (Sept 2019–Aug 2021).","The company highlights upcoming Phase 2 AMPLIFY-7P disease-free survival interim analysis for cancer immunotherapy ELI-002."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":202503322.98607242,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174967,"accession_number":"0001601485-25-000018","cik":1601485,"company_name":"Elicio Therapeutics, Inc.","ticker":"ELTX","form_type":"8-K","filed_at":"2025-03-05T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Elicio Therapeutics (ELTX) settles $20M convertible note, issues 3.5M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Converted $20M 3.0% Senior Secured Convertible Note due Feb 2026 into 3,500,573 common shares on March 5, 2025.","Shares issued to GKCC, LLC, an entity controlled by a board member; exemption under Section 3(a)(9) of Securities Act.","Conversion triggered by stock price closing at or above 135% of $5.81 conversion price for 20 of 30 trading days.","Post-conversion shares outstanding increased to 15,861,913, diluting prior holders by approximately 28%.","Note originally issued in August 2024; conversion eliminates remaining principal and accrued interest."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":202503322.98607242,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174966,"accession_number":"0001193125-25-016455","cik":1601485,"company_name":"Elicio Therapeutics, Inc.","ticker":"ELTX","form_type":"8-K","filed_at":"2025-01-30T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Elicio Therapeutics raises $10M in registered direct offering of shares and warrants","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Gross proceeds of $10.0M from sale of 1,261,830 shares and warrants priced at $7.925 per unit.","Warrants exercisable at $7.80/share for five years, immediately exercisable with 4.99% ownership blocker.","H.C. Wainwright & Co. acted as exclusive placement agent; net proceeds for working capital and general corporate purposes.","Offering closed on January 30, 2025 under effective shelf registration statement (File No. 333-279925)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":202503322.98607242,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174965,"accession_number":"0001601485-25-000009","cik":1601485,"company_name":"Elicio Therapeutics, Inc.","ticker":"ELTX","form_type":"8-K","filed_at":"2025-01-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Elicio posts corporate deck; no extractable clinical/financial data in filing text","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Corporate presentation posted on company website dated January 23, 2025.","Presentation title: 'Targeting the Lymph Nodes to AMPlify Immunotherapy'.","No specific pipeline, financial, or milestone data available from the provided exhibit text.","Standard forward-looking statement disclaimers and market data cautions included."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":202503322.98607242,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174964,"accession_number":"0001601485-25-000006","cik":1601485,"company_name":"Elicio Therapeutics, Inc.","ticker":"ELTX","form_type":"8-K","filed_at":"2025-01-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Elicio receives supportive FDA feedback on ELI-002 Phase 3 registrational strategy","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA aligned on Phase 3 study design: dose, schedule, patient population (KRAS-mutated pancreatic cancer), and DFS endpoint.","Phase 2 AMPLIFY-7P study fully enrolled; interim DFS analysis expected H1 2025.","Positive Phase 2 results could support rapid advancement into Phase 3 and potential BLA filing.","ELI-002 is an off-the-shelf monotherapy for mKRAS cancers patients post-chemotherapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":202503322.98607242,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191935,"accession_number":"0001601485-24-000107","cik":1601485,"company_name":"Elicio Therapeutics, Inc.","ticker":"ELTX","form_type":"8-K","filed_at":"2024-12-12T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Elicio Therapeutics Reports Updated Phase 1 Data for ELI-002 at ESMO Immuno-Oncology Congress 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Updated Phase 1 data show 16.3-month median recurrence-free survival (mRFS) and 28.9-month median overall survival (mOS) from full study population (n=25).","Strong correlation observed between T cell response and reduced risk of progression or death.","Event-driven interim analysis from randomized Phase 2 trial of ELI-002 7P expected in first half of 2025.","ELI-002 was well-tolerated with no Grade 3/4 adverse events or dose-limiting toxicities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":202503322.98607242,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191934,"accession_number":"0001193125-24-269400","cik":1601485,"company_name":"Elicio Therapeutics, Inc.","ticker":"ELTX","form_type":"8-K","filed_at":"2024-12-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Elicio Therapeutics completes enrollment of 135 patients in Phase 2 AMPLIFY-7P study for ELI-002","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2 study ELI-002 7P enrolled 135 mKRAS-driven PDAC patients post-surgery, randomized 2:1 vs observation.","Interim analysis of disease-free survival (DFS) expected in H1 2025, with possible final analysis in H2 2025.","Enrollment pace exceeded expectations; patients eligible cross-over to ELI-002 upon progression.","Primary endpoint is DFS; key secondary endpoints include overall survival and vaccine immunogenicity.","Previous Phase 1a data showed favorable safety and T-cell responses; SITC 2024 data presented."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":202503322.98607242,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191933,"accession_number":"0001601485-24-000083","cik":1601485,"company_name":"Elicio Therapeutics, Inc.","ticker":"ELTX","form_type":"8-K","filed_at":"2024-11-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Elicio Therapeutics shareholders elect directors, ratify auditor, approve share issuance","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Three Class I directors elected: Robert Connelly (6,248,397 for), Katie Chudnovsky (6,233,264), Allen Nissenson (6,249,739).","Ratification of Baker Tilly US, LLP as auditor for FY2024: 7,434,248 for, 1,188 against, 17,558 abstain.","Approved issuance of shares upon exercise of warrants and convertible note per Nasdaq Rule 5635(b): 6,269,593 for, 81,508 against.","Quorum of 7,452,994 shares voted (69.17% of voting power); all proposals passed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":202503322.98607242,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191932,"accession_number":"0001601485-24-000074","cik":1601485,"company_name":"Elicio Therapeutics, Inc.","ticker":"ELTX","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Elicio Therapeutics Q3 2024 net loss $18.8M, cash $26M; AMPLIFY-7P enrollment on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $18.8M ($1.39 per share) vs $10.7M ($1.27) YoY; includes $8.5M non-cash warrant liability change.","Cash and cash equivalents $26.0M as of Sept 30, 2024; operational changes expected to fund into Q2 2025.","AMPLIFY-7P Phase 2 randomized study enrollment completion expected Q4 2024; interim DFS analysis H1 2025.","SITC poster showed durable T cell responses and antigen spreading in KRAS mutant tumors; ESMO oral presentation in Dec 2024.","R&D expense $7.2M, G&A $3.1M; $1.5M grant and $20M convertible notes closed in Q3."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":202503322.98607242,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191931,"accession_number":"0001601485-24-000067","cik":1601485,"company_name":"Elicio Therapeutics, Inc.","ticker":"ELTX","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Elicio reports ELI-002 Phase 1 data: T cell responses correlate with DFS; Phase 2 enrollment expected Q4 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 12 evaluable patients showed mKRAS-specific T cell responses; RP2D group had 12-fold higher median response vs 1.4 mg group.","T cell response magnitude correlated with DFS: lowest quartile mDFS 3.1 months (p=0.0027), top three quartiles not yet reached.","Antigen spreading in 100% of RP2D-treated patients (n=6); T cells targeted 67.5% of patient-specific neoantigens.","ELI-002 remains safe and well-tolerated; no dose-limiting toxicities or cytokine release syndrome observed.","Phase 2 enrollment expected to complete in Q4 2024; interim event-driven DFS analysis expected H1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":202503322.98607242,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191930,"accession_number":"0001601485-24-000063","cik":1601485,"company_name":"Elicio Therapeutics, Inc.","ticker":"ELTX","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Elicio Therapeutics annual meeting adjourned due to lack of quorum; reconvened Nov 21","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Virtual annual meeting on Nov 7, 2024 lacked a quorum of common stock holders.","Meeting adjourned to Nov 21, 2024 at 9:30 a.m. ET; no in-person attendance.","Existing proxies remain valid; new proxy voting deadline is Nov 20, 2024 11:59 p.m. ET.","Record date remains Sept 11, 2024; preregistered stockholders need not re-register.","Majority of received proxies voted in favor of all proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":202503322.98607242,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191929,"accession_number":"0001601485-24-000057","cik":1601485,"company_name":"Elicio Therapeutics, Inc.","ticker":"ELTX","form_type":"8-K","filed_at":"2024-10-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Elicio Therapeutics appoints CEO Robert Connelly as Principal Financial and Accounting Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert Connelly, already CEO and President, appointed as Principal Accounting Officer and Principal Financial Officer effective Oct 15, 2024.","Connelly has nearly 40 years of life science leadership; previously CEO of Axcella Health, Pulmatrix, and Domantis (acquired by GSK).","No family relationships with other directors or executive officers; no reportable transactions under Item 404(a)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":202503322.98607242,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208389,"accession_number":"0001140361-24-039592","cik":1601485,"company_name":"Elicio Therapeutics, Inc.","ticker":"ELTX","form_type":"8-K","filed_at":"2024-08-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Elicio Therapeutics CFO Brian Piekos resigns effective September 6, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Brian Piekos notified Company of resignation on Aug 27, 2024, to pursue other opportunity.","Resignation effective September 6, 2024; no disagreement on financial reporting or accounting matters.","Company has initiated search for a new Chief Financial Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":202503322.98607242,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208388,"accession_number":"0001601485-24-000042","cik":1601485,"company_name":"Elicio Therapeutics, Inc.","ticker":"ELTX","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Elicio Q2 net loss $7.2M; Phase 1 data show 100% T cell response; Phase 2 enrollment Q4","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $7.2M ($0.64 per share) for Q2 2024; cash $3.4M at June 30, but subsequent financings raised ~$29.6M net.","AMPLIFY-7P Phase 1 data: 100% of patients developed mKRAS-specific T-cell response; median DFS not reached at RP2D (4.9mg).","Phase 2 randomized trial enrollment expected to complete Q4 2024; interim analysis anticipated Q1 2025.","AMPLIFY-201 long-term follow-up to be terminated; updated data at upcoming medical meetings."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.77,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":202503322.98607242,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208387,"accession_number":"0001140361-24-036848","cik":1601485,"company_name":"Elicio Therapeutics, Inc.","ticker":"ELTX","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["1.01","2.03","3.02","8.01","9.01"],"status":"ready","headline":"Elicio Therapeutics closes $20M convertible note private placement at $5.81 conversion price","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Raised $20M via 3% senior secured convertible note due Feb 2026; net proceeds ~$19.7M.","Conversion price $5.81 per share (~135% of Aug 9 close); subject to stockholder approval.","Purchaser GKCC LLC is controlled by a board member (related-party transaction).","Proceeds to be used for working capital and general corporate purposes.","Note is secured by first-priority lien on substantially all assets and intellectual property."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":202503322.98607242,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208386,"accession_number":"0001140361-24-031811","cik":1601485,"company_name":"Elicio Therapeutics, Inc.","ticker":"ELTX","form_type":"8-K","filed_at":"2024-07-01T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Elicio Therapeutics prices $11.5M public offering of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$11.5M; net proceeds ~$10.9M after discounts and expenses.","Offering consists of 500K shares and 1.8M pre-funded warrants, each with common warrants exercisable at $5.00 for 5 years.","Combined price: $5.00 per share+common warrant; $4.99 per pre-funded warrant+common warrant.","Expected to close July 1, 2024; proceeds to advance development pipeline and for working capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":202503322.98607242,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226068,"accession_number":"0001140361-24-031563","cik":1601485,"company_name":"Elicio Therapeutics, Inc.","ticker":"ELTX","form_type":"8-K","filed_at":"2024-06-27T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Elicio reports ELI-002 7P Phase 1a DFS not yet reached at 4.9mg; biomarker responders have no progression","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Median DFS not reached in 14 patients; median follow-up 29.1 weeks.","At 4.9mg AMP-peptide (n=8), median DFS not reached vs 12.6 weeks for 1.4mg (n=6).","Patients with tumor biomarker reduction had zero progression events; non-responders had median DFS 11.0 weeks.","Above-median T cell responders had no progression events as of May 24, 2024 data cutoff.","Phase 2 interim analysis (135 patients) expected Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":202503322.98607242,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226067,"accession_number":"0001601485-24-000037","cik":1601485,"company_name":"Elicio Therapeutics, Inc.","ticker":"ELTX","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Elicio reports preliminary Phase 1a data for ELI-002 7P: 100% T cell response, biomarker reductions","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ELI-002 7P generated mKRAS-specific T cell response in 100% (11/11) evaluable patients; responses against all mutations enrolled.","At 4.9 mg RP2D, 66.7% (4/6) had both CD8+ and CD4+ responses; biomarker reductions in 71% (5/7) evaluable patients.","Antigen-spreading observed: T cell responses targeting non-immunizing tumor neoantigens in 100% (6/6) at RP2D.","No dose-limiting toxicities, no treatment-related serious adverse events or cytokine release syndrome.","Recommended Phase 2 dose: 4.9 mg AMP-Peptides 7P with 10 mg AMP-CpG-7909."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":202503322.98607242,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226066,"accession_number":"0001601485-24-000032","cik":1601485,"company_name":"Elicio Therapeutics, Inc.","ticker":"ELTX","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Elicio Therapeutics reports Q1 2024 net loss of $11.8M; provides clinical updates for ELI-002","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $11.8M ($1.15 per share) vs $8.0M in Q1 2023; R&D expense increased to $7.6M from $5.5M.","Cash and equivalents $11.9M as of March 31, 2024, down from $12.9M at December 31, 2023.","ELI-002 2P Phase 1 data published in Nature Medicine; ELI-002 7P Phase 1 preliminary data at ASCO in June 2024.","Randomized Phase 2 trial of ELI-002 7P enrollment expected to complete in Q4 2024; interim analysis in Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":202503322.98607242,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226065,"accession_number":"0001601485-24-000025","cik":1601485,"company_name":"Elicio Therapeutics, Inc.","ticker":"ELTX","form_type":"8-K","filed_at":"2024-04-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Elicio reports 84% CD8+ T cell response and antigen spreading in ELI-002 Phase 1 at AACR","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["68% of patients developed cytotoxic mKRAS-specific CD4+ T cells; 84% developed CD8+ T cells.","Majority of patients showed antigen spreading: T cells targeted additional patient-specific tumor mutations beyond mKRAS.","Booster doses maintained/increased mKRAS-specific T cell response with increased memory phenotype; no regulatory T cell response detected.","Preclinical ELI-007 and ELI-008 showed 42-fold to several-hundred-fold increased immune response vs. conventional vaccines.","Initial clinical data for ELI-002 7P expected in Q2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":202503322.98607242,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245151,"accession_number":"0001601485-24-000021","cik":1601485,"company_name":"Elicio Therapeutics, Inc.","ticker":"ELTX","form_type":"8-K","filed_at":"2024-03-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Elicio Therapeutics reports FY2023 net loss $35.2M; cash boosted by $6M private placement","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $35.2M for FY2023 vs $28.2M in FY2022; diluted EPS -$6.96 vs -$89.27 (reverse-merger impact).","Cash and cash equivalents $12.9M at Dec 31, 2023; $6.0M private placement closed in March 2024.","ELI-002 2P Phase 1a data in Nature Medicine: 84% T cell response, 24% biomarker clearance, median RFS 16.33 months.","Phase 2 randomized trial of ELI-002 7P in PDAC started; enrollment expected to complete Q4 2024.","Initial clinical data from ELI-002 7P Phase 1 trial anticipated in Q2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":202503322.98607242,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245150,"accession_number":"0001601485-24-000015","cik":1601485,"company_name":"Elicio Therapeutics, Inc.","ticker":"ELTX","form_type":"8-K","filed_at":"2024-03-18T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Elicio raises $6.0M via pre-funded warrants sale to board-member entity GKCC, LLC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Private placement of pre-funded warrants for 1,032,702 shares at $5.81 each; gross proceeds ~$6.0M.","Warrants exercisable at $0.01/share subject to 19.99% beneficial ownership cap unless stockholder approval obtained.","Purchaser GKCC, LLC is controlled by a member of Elicio's board of directors.","Closing expected March 19, 2024; proceeds for pipeline advancement and working capital.","Company must file resale registration statement with SEC by June 30, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":202503322.98607242,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245149,"accession_number":"0001601485-24-000013","cik":1601485,"company_name":"Elicio Therapeutics, Inc.","ticker":"ELTX","form_type":"8-K","filed_at":"2024-02-02T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Elicio raises CEO/CSO base pay, grants 225k/30k stock options, adopts severance plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO base salary raised to $608,400; annual performance bonus opportunity set at 55% of base.","CSO base salary increased to $460,000; annual performance bonus opportunity set at 40% of base.","Stock options granted: 225,137 shares to CEO, 29,800 shares to CSO; vest 25% on first anniversary then monthly.","New Executive Severance Plan provides salary-based multipliers for normal and change-in-control severance, plus equity acceleration.","Severance benefits require a release and are conditioned on compliance with restrictive covenants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":202503322.98607242,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245148,"accession_number":"0001601485-24-000009","cik":1601485,"company_name":"Elicio Therapeutics, Inc.","ticker":"ELTX","form_type":"8-K","filed_at":"2024-01-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Elicio presents ELI-002 7P Phase 1/2 trial design at ASCO GI; Phase 1A complete, Phase 2 enrolling","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1A completed with no dose-limiting toxicities; Phase 2 randomized 2:1 study enrolling PDAC patients.","ELI-002 7P targets seven KRAS mutations driving 25% of solid tumors using AMP lymph node-targeting platform.","First patient dosed in randomized Phase 2 cohort comparing ELI-002 7P to standard of care (observation).","Previous 2-peptide formulation published in Nature Medicine showed tumor biomarker reduction and reduced risk of relapse/death."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":202503322.98607242,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245147,"accession_number":"0001601485-24-000006","cik":1601485,"company_name":"Elicio Therapeutics, Inc.","ticker":"ELTX","form_type":"8-K","filed_at":"2024-01-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Elicio raises ~$4.9M from ATM equity sales since Q3 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued and sold 584,170 shares under at-the-market program since September 30, 2023.","Net proceeds of approximately $4.89 million after deducting sales commissions.","Original ATM program authorized up to $21.0 million in aggregate offering price.","Program is ongoing with Stifel and Virtu Americas LLC as agents."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":202503322.98607242,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245146,"accession_number":"0001140361-24-001416","cik":1601485,"company_name":"Elicio Therapeutics, Inc.","ticker":"ELTX","form_type":"8-K","filed_at":"2024-01-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Elicio reports Phase 1 data for ELI-002: 84% T cell response, 16.3-month median RFS","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["AMPLIFY-201 data published in Nature Medicine in 25 patients (20 pancreatic, 5 colorectal) with minimal residual mKRAS disease.","ELI-002 induced direct ex vivo mKRAS-specific T cell responses in 84% of patients; 59% both CD4+ and CD8+.","84% of patients had tumor biomarker reduction; 24% achieved complete biomarker clearance.","Median relapse-free survival was 16.33 months; high T cell responders had 86% reduction in risk of progression or death.","Phase 2 monotherapy trial in pancreatic ductal adenocarcinoma planned to start early 2024; no safety concerns identified."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":202503322.98607242,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262583,"accession_number":"0001601485-23-000086","cik":1601485,"company_name":"Elicio Therapeutics, Inc.","ticker":"ELTX","form_type":"8-K","filed_at":"2023-12-22T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Elicio Therapeutics raises $7M via private placement at $5.81/share to board-affiliated entity","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Private placement of 1,213,000 shares at $5.81 per share to GKCC, LLC, controlled by a board member.","Gross proceeds of ~$7.0M; net proceeds for pipeline advancement, working capital, and general corporate purposes.","Closing expected on December 22, 2023, subject to customary conditions.","Company must file a resale registration statement with SEC by March 31, 2024.","Securities are unregistered; sold under Section 4(a)(2) and Rule 506 of Regulation D."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":202503322.98607242,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262582,"accession_number":"0001601485-23-000077","cik":1601485,"company_name":"Elicio Therapeutics, Inc.","ticker":"ELTX","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Elicio Therapeutics Q3 net loss $10.7M; ELI-002 RFS 16.3 months, Phase 2 planned early 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $10.7M ($1.27/sh) vs $7.2M loss ($22.67/sh) in Q3 2022; cash $14.1M vs $6.2M year-end 2022.","ELI-002 2P showed median relapse-free survival of 16.3 months; T-cell response correlated with 86% risk reduction (HR 0.14, p=0.013).","ELI-002 7P Phase 2 monotherapy trial in adjuvant PDAC to start early 2024; interim analysis expected Q1 2025.","R&D expense $7.3M (+58% YoY) and G&A $3.5M (+198% YoY) driven by public company costs and trial expansion."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":202503322.98607242,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262581,"accession_number":"0001601485-23-000071","cik":1601485,"company_name":"Elicio Therapeutics, Inc.","ticker":"ELTX","form_type":"8-K","filed_at":"2023-11-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Elicio reports ELI-002 Phase 1 data: 87% T cell response, 86% reduced relapse risk; new preclinical data","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ELI-002 Phase 1: 87% (20/23) of patients had direct ex vivo mKRAS-specific T cell responses; 100% in vitro.","T cell response strength correlated with 86% reduced risk of relapse and death in pancreatic/colorectal cancer.","In 4 patients assessed post-boost, 100% maintained elevated T cell responses, 75% increased further.","ELI-007 and ELI-008 preclinical: >10-500-fold higher T cell responses vs. conventional comparators in mice.","Data presented at SITC 2023; supports lymph node-targeting AMP platform for solid tumors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":202503322.98607242,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262580,"accession_number":"0001601485-23-000065","cik":1601485,"company_name":"Elicio Therapeutics, Inc.","ticker":"ELTX","form_type":"8-K","filed_at":"2023-10-20T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Elicio Therapeutics announces departure of Chief Business Officer Annette Matthies effective Oct 19, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Annette Matthies, Ph.D. ceased as Chief Business Officer; separation agreement signed October 19, 2023.","Company will pay six months of base salary and reimburse COBRA premiums for up to six months.","Separation includes standard release of claims and confidentiality covenants.","No replacement or successor has been named; reason for departure not disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":202503322.98607242,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262579,"accession_number":"0001601485-23-000062","cik":1601485,"company_name":"Elicio Therapeutics, Inc.","ticker":"ELTX","form_type":"8-K","filed_at":"2023-10-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Elicio Therapeutics terminates Chief Business Officer Annette Matthies without cause","summary_kind":"llm","event_type":"leadership","confidence":"medium","bullets":["Annette Matthies, Ph.D., Chief Business Officer, terminated without cause effective October 5, 2023.","No replacement or interim successor named in the filing.","Separation is effective as of the date of termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":202503322.98607242,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279791,"accession_number":"0001601485-23-000060","cik":1601485,"company_name":"Elicio Therapeutics, Inc.","ticker":"ELTX","form_type":"8-K","filed_at":"2023-09-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Elicio reports ELI-002 Phase 1 data: median RFS not reached vs 3.9 months, HR=0.14","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Median RFS not reached for high T cell responders vs 3.9 months for low (HR=0.14; p=0.013).","86% reduction in risk of progression or death in patients with large T cell responses.","Tumor biomarker reduction/clearance -86.9% vs -1.0% in above vs below median T cell responders (p<0.0017).","Plan to initiate randomized Phase 2 study of ELI-002 7P in adjuvant PDAC patients early 2024.","No ≥Grade 3 treatment-related AEs; safety profile supports further development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":202503322.98607242,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279790,"accession_number":"0001601485-23-000057","cik":1601485,"company_name":"Elicio Therapeutics, Inc.","ticker":"ELTX","form_type":"8-K","filed_at":"2023-09-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Elicio Therapeutics receives $2.6M grant from GI Research Foundation for two cancer vaccines","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Grant awarded on Sept 7, 2023, adds to $2.8M received in Sept 2022 from GIRF.","Funds will advance ELI-007 (mutant BRAF-peptide) and ELI-008 (p53 hotspot mutation-peptide) vaccines.","Vaccines use Elicio's AMP lymph node-targeting platform; CMC, regulatory, and clinical prep underway.","BRAF V600E mutations seen in 40% melanoma, 10% colon, 2% lung; p53 mutations in ~30% solid tumors.","Non-dilutive funding supports IND planning and initial patient clinical assessment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":202503322.98607242,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279789,"accession_number":"0001601485-23-000055","cik":1601485,"company_name":"Elicio Therapeutics, Inc.","ticker":"ELTX","form_type":"8-K","filed_at":"2023-08-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Elicio Therapeutics director Assaf Segal resigns effective August 28, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Assaf Segal resigned from the Board of Elicio Therapeutics, effective immediately on August 28, 2023.","Resignation follows his planned departure as CEO of Clal Biotechnology Industries, not due to any disagreement.","No replacement named; the Board continues with remaining members."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":202503322.98607242,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279787,"accession_number":"0001140361-23-039343","cik":1601485,"company_name":"Elicio Therapeutics, Inc.","ticker":"ELTX","form_type":"8-K/A","filed_at":"2023-08-14T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Elicio files historical financials of Private Elicio post-merger; Q1 net loss $8.0M, going concern flagged","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Private Elicio net loss of $8.0M for Q1 2023; accumulated deficit $115.0M at March 31, 2023.","Cash and equivalents of $8.6M at March 31, 2023; negative operating cash flow of $8.1M in Q1.","Auditor's going concern opinion citing losses, negative cash flows, and need for additional financing.","Merger with Angion closed June 1, 2023; company renamed Elicio Therapeutics, now trading as ELTX.","Pro forma combined financials filed; no revenue for Private Elicio in the periods presented."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":202503322.98607242,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-08-14T23:59:59+00:00|279787"}